There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.

Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

00:52-04:09: About Terran Biosciences
04:09-06:03: What are the challenges of using psychedelics?
06:03-07:32: Is there still a stigma attached to use of psychedelics?
07:32-11:45: How do psychedelics work on the brain?
11:45-13:44: Why are psychedelics a good treatment?
13:44-16:51: What is Idazoxan XR?
16:51-18:01: How do you make changes to drugs?
18:01-21:19: How did you develop your business model?
21:19-22:40: What are Eplivanserin and Volinanserin?
22:40-24:49: How useful are repurposed drugs?
24:49-29:06: Keeping drugs affordable
29:06-30:31: Dealing with patents
30:31-32:41: What are empathogens?
32:41-33:12: Where is the company at with clinical trials?
33:12-35:45: What is NM-101?
35:45-37:47: How does Terran differ from other companies?
37:47-39:54: Are you looking to cure conditions?
39:54-40:48: Schizophrenia

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Reformulating psychedelics for neurodegenerative diseases